BGI Co-Win is an investment fund operating as the corporate venture capital arm of BGI, which is headquartered in Shenzhen, China. The fund is specialized in financing initiatives and enterprises in the life sciences sector. Their investment focus encompasses several innovative fields, including medical technology, gene technology, and biomedical companies. As investors, they leverage the comprehensive scientific background and resources of BGI to support portfolio companies in these areas. BGI Co-Win's investment thesis revolves around identifying and nurturing early to mid-stage companies that can benefit from BGI's expertise in genomics and biotechnology, while also offering growth potential and strategic alignment with BGI's long-term interests. By doing so, the fund aims to foster the development of cutting-edge healthcare technologies and solutions that could lead to substantial advancements in the field of life sciences, and correspondingly provide societal benefits in the form of enhanced medical capabilities. Due to their deep-rooted connections with BGI, BGI Co-Win is well-positioned to facilitate the growth of their investee companies through not only capital investment but also through providing access to a broad network of industry partners, scientific resources, and market insights, thereby enabling these companies to achieve scale, innovation, and reach critical milestones in their development.